Developmental Research (Ingle)

发展研究（英格尔）

• 批准号: 8744966
• 负责人: JAMES Newell INGLE
• 金额: $ 21.87万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-22 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8744966
• 关键词: Achievement; Advisory Committees; Advocacy; Annual Reports; Applications Grants; Award; Biostatistics Core; Breast; Cancer Patient; Clinic; Clinical Research; Clinical Trials; Commit; Communities; Creativeness; Data; Detection; Development; Diagnosis; Disabled Persons; Disease; Ensure; Evaluation; Extramural Activities; Funding; Future; Generations; Goals; Grant; Guidelines; Human Resources; Incidence; Judgment; Laboratory Study; Lead; Leadership; Mayo Clinic Cancer Center; Mentors; Minority; Monitor; Pathology; Peer Review; Pilot Projects; Policies; Population Study; Prevention; Procedures; Process; Program Research Project Grants; Progress Reports; Qualifying; Quality of life; Reporting; Research; Research Personnel; Research Project Grants; Scientist; Secure; Selection Criteria; Site Visit; Specific qualifier value; Stimulus; Testing; Time; Translating; Translational Research; Woman; Work; Writing; anticancer research; base; career development; expectation; experience; innovation; interdisciplinary collaboration; malignant breast neoplasm; meetings; member; mortality; originality; patient registry; preclinical study; programs; success; symposium

The Mayo Clinic Breast Cancer SPORE will maximize the number of innovative and high-quality projects in the Developmental Research Program. The goal of this program is to support innovative, scientifically meritorious research projects from which findings can be translated into clinically important applications that will impact diagnosis and management of breast cancer in order to decrease the burden and mortality from this disease. This program will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals; 2) encourage and support interdisciplinary collaboration in translational research in breast cancer; and 3) generate new hypotheses that can be tested in larger-scale research projects or clinical trials that can impact breast cancer. The availability of this support provides a stimulus for creativity in the research community, a vehicle for encouraging the interaction of basic scientists and translational investigators, and an opportunity for expanding the research spectrum of the SPORE by pursuing new leads based on discoveries and/or opportunities that arise. The Developmental Research Program will provide $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from Mayo Clinic Cancer Center) to each of six projects. There will be the possibility of a second year of support based on demonstration of sufficient progress. A process was established during the initial grant for the Mayo Clinic Breast Cancer SPORE involving a call for applications on an annual basis and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Because of the success of this process, it will be continued. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer reviewed external grant support. It is the intent of the SPORE leadership to encourage and help the investigators to use the data generated by these projects to establish preclinical or clinical trials in breast cancer. In addition the SPORE leadership will work with the investigators to secure independent R01-level funding. Two of the four full Projects in this SPORE renewal have a co-leader who was a Developmental Research Program awardee, which indicates that the Developmental Research Program has been successful in this regard during the previous funding period.

梅奥诊所乳腺癌 SPORE 将最大限度地增加发展研究计划中创新和高质量项目的数量。该计划的目标是支持创新的、有科学价值的研究项目，这些项目的研究结果可以转化为临床重要的应用，这将影响乳腺癌的诊断和管理，以减少这种疾病的负担和死亡率。该计划将：1）鼓励和征求创新的转化实验室、人群和临床研究提案； 2）鼓励和支持乳腺癌转化研究的跨学科合作； 3）产生新的假设，可以在影响乳腺癌的更大规模的研究项目或临床试验中进行测试。这种支持的提供激发了研究界的创造力，是鼓励基础科学家和转化研究人员互动的工具，也是通过根据发现和/或出现的机会寻求新线索来扩大 SPORE 研究范围的机会。发展研究计划将为六个项目中的每一个项目提供一年 50,000 美元（其中 25,000 美元来自 SPORE 基金，配套的 25,000 美元来自 Mayo Clinic 癌症中心）。如果取得了足够的进展，就有可能提供第二年的支持。在梅奥诊所乳腺癌孢子的初始拨款期间建立了一个流程，包括每年征集申请以及利用内部科学咨询委员会和其他经验丰富的研究人员的专业知识进行正式的同行评审。由于这一过程的成功，它将继续下去。资助项目的选择标准基于科学价值、原创性、申请人的资格和转化潜力。预计对发展研究项目的支持将产生数据，这些数据将作为 SPORE 资助的其他项目或通过同行评审的外部赠款支持提供支持的基础。 SPORE 领导层的目的是鼓励和帮助研究人员使用这些项目生成的数据来建立乳腺癌的临床前或临床试验。此外，SPORE 领导层将与研究人员合作，确保独立的 R01 级资金。本次 SPORE 更新的四个完整项目中有两个项目的联合领导者是发展研究计划获奖者，这表明发展研究计划在上一个资助期间在这方面取得了成功。